Secukinumab Provides Clinical Benefit for JIA Subtypes Secukinumab Provides Clinical Benefit for JIA Subtypes
Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 16, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Arthritis symptoms: Four 'weird and unusual' signs of arthritis pain you might be missing
ARTHRITIS symptoms usually include joint pain and inflammation, but the signs could also be more subtle. These are the four most common "weird and unusual" symptoms of psoriatic arthritis that you might be missing - should you speak to a doctor? (Source: Daily Express - Health)
Source: Daily Express - Health - June 16, 2021 Category: Consumer Health News Source Type: news
What Does a Psoriatic Arthritis Rash Look Like
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news
What Are the Five Types of Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news
What Foods Make Psoriatic Arthritis Worse
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 8, 2021 Category: General Medicine Source Type: news
What Is the Best Treatment for Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 7, 2021 Category: General Medicine Source Type: news
New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more diffic...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Fecal Transplantation Safe but Ineffective in PsA Trial Fecal Transplantation Safe but Ineffective in PsA Trial
A trial found fecal microbiota transplantation in psoriatic arthritis inferior to sham but safe, and investigators said it ' s worthy of future study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 8, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMFYA is t...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Jo...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
What Can Mimic Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 20, 2021 Category: General Medicine Source Type: news
Arthritis symptoms: Nail changes are a ‘strong predictor’ of arthritis - what to look for
Arthritis is a common condition that causes pain and inflammation in a joint. Arthritis comes in many forms and nail changes are predictive of a type of arthritis called psoriatic arthritis. (Source: Daily Express - Health)
Source: Daily Express - Health - April 6, 2021 Category: Consumer Health News Source Type: news
Will Psoriatic Arthritis Cripple Me?
Title: Will Psoriatic Arthritis Cripple Me?Category: Diseases and ConditionsCreated: 4/5/2021 12:00:00 AMLast Editorial Review: 4/5/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 5, 2021 Category: Rheumatology Source Type: news
Upadacitinib Beats Placebo for Psoriatic Arthritis
WEDNESDAY, March 31, 2021 -- For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine.
Iain... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2021 Category: Pharmaceuticals Source Type: news
